Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2013 | Original Article

¹⁸F-Fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma

Authors: Myeong Jun Song, Si Hyun Bae, Sung Won Lee, Do Sun Song, Hee Yeon Kim, Ie Ryung Yoo, Joon-IL Choi, Young June Lee, Ho Jong Chun, Hae Giu Lee, Jong Young Choi, Seung Kew Yoon

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2013

Abstract

Purpose

¹⁸F-FDG PET monitoring of FDG uptake may be a useful tool for assessment of the biological behaviour of hepatocellular carcinoma (HCC). We evaluated the correlation between FDG uptake on ¹⁸F-FDG PET and clinical characteristics and prognosis.

Methods

In total, 58 HCC patients undergoing ¹⁸F-FDG PET before transarterial chemoembolization (TACE) between May 2007 and May 2010 at Seoul St. Mary’s Hospital were evaluated retrospectively. The predictive value of the ratio of maximal tumour standardized uptake value (SUV) to mean liver SUV (Tsuv _max/Lsuv _mean) was tested. Primary endpoints were the clinical characteristics and treatment response according to Tsuv _max/Lsuv _mean. The secondary endpoint was time to progression (TTP).

Results

A high SUV ratio (cutoff value 1.70) correlated significantly with tumour size (≥5 cm) and serum AFP level (≥400 ng/mL). Objective response rates were significantly different between those with a ratio above (15.7 %) and those with a ratio below (66.6 %) the cutoff value (P = 0.023). Patients in the low SUV ratio group had a median TTP of 16.8 months compared with 8.1 months in the high SUV ratio group (P = 0.011). Overall survival in the high SUV ratio group was worse than in the low SUV ratio group (median 56.5 vs. 23.3 months), although the difference was not statistically significant in a multivariate analysis.

Conclusion

Tumour metabolic activity (Tsuv _max/Lsuv _mean), assessed by PET/CT, is an independent predictor of response to TACE in patients with intermediate-stage HCC. Tsuv _max/Lsuv _mean can be used to predict tumour progression. Thus, ¹⁸F-FDG PET can provide valuable information for prediction of prognosis and aid in decisions regarding treatment strategy.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef

Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17. doi:10.1016/S0140-6736(03)14964-1.PubMedCrossRef

Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2. doi:10.1002/hep.24199.PubMedCrossRef

Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502–10. doi:10.1111/j.1478-3231.2008.01957.x.PubMedCrossRef

Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2012;81:2417–22. doi:10.1016/j.ejrad.2011.08.004.PubMedCrossRef

Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3314–9. doi:10.1111/j.1572-0241.1999.01544.x.PubMedCrossRef

Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS, et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging. 2004;31:1621–30. doi:10.1007/s00259-004-1602-1.PubMedCrossRef

Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl. 2006;12:1655–60. doi:10.1002/lt.20861.PubMedCrossRef

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi:10.1055/s-0030-1247132.PubMedCrossRef

10.

Busk M, Horsman MR, Kristjansen PE, van der Kogel AJ, Bussink J, Overgaard J. Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer. 2008;122:2726–34. doi:10.1002/ijc.23449.PubMedCrossRef

11.

Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol. 2009;174:1544–52. doi:10.2353/ajpath.2009.080596.PubMedCrossRef

12.

Mocherla B, Kim J, Roayaie S, Kim S, Machac J, Kostakoglu L. FDG PET/CT imaging to rule out extrahepatic metastases before liver transplantation. Clin Nucl Med. 2007;32:947–8. doi:10.1097/RLU.0b013e3181598cef.PubMedCrossRef

13.

Higashi T, Hatano E, Ikai I, Nishii R, Nakamoto Y, Ishizu K, et al. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:468–82. doi:10.1007/s00259-009-1284-9.PubMedCrossRef

14.

Lee JH, Park JY, Kim do Y, Ahn SH, Han KH, Seo HJ, et al. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int. 2011;31:1144–9. doi:10.1111/j.1478-3231.2011.02541.x.PubMedCrossRef

15.

Kornberg A, Kupper B, Tannapfel A, Buchler P, Krause B, Witt U, et al. Patients with non-[18F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl. 2012;18:53–61. doi:10.1002/lt.22416.PubMedCrossRef

16.

Song MJ, Bae SH, Yoo Ie R, Park CH, Jang JW, Chun HJ, et al. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol. 2012;18:3215–22. doi:10.3748/wjg.v18.i25.3215.PubMed

17.

Ahn SG, Kim SH, Jeon TJ, Cho HJ, Choi SB, Yun MJ, et al. The role of preoperative [18F]fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas. J Gastrointest Surg. 2011;15:2044–52. doi:10.1007/s11605-011-1660-1.PubMedCrossRef

18.

Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim do Y. (18)F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer. 2011;117:4779–87. doi:10.1002/cncr.26099.PubMedCrossRef

19.

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711. doi:10.1093/jnci/djn134.PubMedCrossRef

20.

Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9. doi:10.1016/S0140-6736(02)08649-X.PubMedCrossRef

21.

Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127:S179–88.PubMedCrossRef

22.

Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–73. doi:10.1002/hep.23725.PubMedCrossRef

23.

Iwata Y, Shiomi S, Sasaki N, Jomura H, Nishiguchi S, Seki S, et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med. 2000;14:121–6.PubMedCrossRef

24.

Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36:1811–7.PubMed

25.

Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A, et al. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med. 2008;49:1245–8. doi:10.2967/jnumed.108.052639.PubMedCrossRef

26.

Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13:427–33. doi:10.1158/1078-0432.CCR-06-1357.PubMedCrossRef

27.

Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet. 1967;2:1051–6.PubMedCrossRef

28.

Petrides AS, DeFronzo RA. Glucose metabolism in cirrhosis: a review with some perspectives for the future. Diabetes Metab Rev. 1989;5:691–709.PubMedCrossRef

29.

Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, Futatsubashi M, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol. 2004;39:961–8. doi:10.1007/s00535-004-1427-5.PubMedCrossRef

30.

Ledoux S, Yang R, Friedlander G, Laouari D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res. 2003;63:7284–90.PubMed

31.

Song MJ, Chun HJ, Song do S, Kim HY, Yoo SH, Park CH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57:1244–50. doi:10.1016/j.jhep.2012.07.017.PubMedCrossRef

32.

Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920–8. doi:10.1111/j.1600-6143.2009.02695.x.PubMedCrossRef

33.

Chiesa C, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging. 2011;55:168–97.PubMed

34.

Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53:255–63. doi:10.2967/jnumed.111.094235.PubMedCrossRef

35.

Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141:526–35, 535 e1-2. doi:10.1053/j.gastro.2011.04.054.PubMedCrossRef

Title: 18F-Fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma
Authors: Myeong Jun Song
Si Hyun Bae
Sung Won Lee
Do Sun Song
Hee Yeon Kim
Ie Ryung Yoo
Joon-IL Choi
Young June Lee
Ho Jong Chun
Hae Giu Lee
Jong Young Choi
Seung Kew Yoon
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2366-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

¹⁸F-Fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2013

Reply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy

Nuclear medicine training and practice in France

Functional imaging of head and neck squamous cell carcinoma with diffusion-weighted MRI and FDG PET/CT: quantitative analysis of ADC and SUV

Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET

Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions